Larazotide acetate has gone further through formal drug development than almost anything else in this newsletter’s coverage, including Phase 3 clinical trials for celiac disease — a genuinely unusual pedigree for a compound that now also shows up in general-purpose “gut health” listings.
What the Celiac Trials Actually Tested
The clinical program studied larazotide’s effect on intestinal tight junctions in people with celiac disease consuming gluten, aiming to reduce the immune and symptomatic response to accidental gluten exposure — a specific mechanism in a specific disease population.
“It’s one of the better-studied compounds we cover, for a disease most of the people buying it don’t have.”
— a gastroenterology researcher who reviewed the trial record for this pieceThe Jump to General Gut-Health Marketing
Tight-junction regulation is relevant to intestinal permeability broadly, which is the mechanistic thread marketing uses to extend the compound to people without celiac disease. The celiac trial data doesn’t speak to that broader population or use case.
Where the Clinical Program Stands
As of this writing, larazotide has not received FDA approval; its clinical development has continued through multiple trial phases without yet reaching that finish line — a different status than an approved drug, but still a more developed evidence base than most compounds covered here.